Deciphering breast cancer: from biology to the clinic
E Nolan, GJ Lindeman, JE Visvader - Cell, 2023 - cell.com
Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …
Targeting CDK4 and CDK6 in cancer
S Goel, JS Bergholz, JJ Zhao - Nature Reviews Cancer, 2022 - nature.com
Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …
transition into S phase and are important for the initiation, growth and survival of many …
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned …
SRD Johnston, M Toi, J O'Shaughnessy… - The lancet …, 2023 - thelancet.com
Background Adjuvant abemaciclib plus endocrine therapy previously showed a significant
improvement in invasive disease-free survival and distant relapse-free survival in hormone …
improvement in invasive disease-free survival and distant relapse-free survival in hormone …
[HTML][HTML] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast …
HJ Burstein, G Curigliano, B Thürlimann, WP Weber… - Annals of oncology, 2021 - Elsevier
The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …
Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
Ribociclib plus endocrine therapy in early breast cancer
D Slamon, O Lipatov, Z Nowecki… - … England Journal of …, 2024 - Mass Medical Soc
Background Ribociclib has been shown to have a significant overall survival benefit in
patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 …
patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 …
[HTML][HTML] Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
N Harbeck, P Rastogi, M Martin, SM Tolaney… - Annals of …, 2021 - Elsevier
Background Adjuvant abemaciclib combined with endocrine therapy (ET) previously
demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) …
demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) …
Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer—the penelope-B trial
S Loibl, F Marmé, M Martin, M Untch… - Journal of clinical …, 2021 - ascopubs.org
PURPOSE About one third of patients with hormone receptor–positive, human epidermal
growth factor receptor 2–negative breast cancer who have residual invasive disease after …
growth factor receptor 2–negative breast cancer who have residual invasive disease after …
[HTML][HTML] Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences
CL Braal, EM Jongbloed, SM Wilting, RHJ Mathijssen… - Drugs, 2021 - Springer
The cyclin-dependent kinase (CDK) 4/6 inhibitors belong to a new class of drugs that
interrupt proliferation of malignant cells by inhibiting progression through the cell cycle …
interrupt proliferation of malignant cells by inhibiting progression through the cell cycle …
CDK4 and CDK6 kinases: From basic science to cancer therapy
A Fassl, Y Geng, P Sicinski - Science, 2022 - science.org
BACKGROUND Cyclins and cyclin-dependent kinases (CDKs) drive cell division. Of
particular importance to the cancer field are D-cyclins, which activate CDK4 and CDK6. In …
particular importance to the cancer field are D-cyclins, which activate CDK4 and CDK6. In …